Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2 Dose-Finding Study Followed by Expansion Cohorts of NGM120, a GFRAL Antagonist Monoclonal Antibody Blocking GDF15 Signaling, in Subjects With Advanced Solid Tumors and Pancreatic Cancer Using Combination Therapy

NCT04068896 is registered in ClinicalTrials.gov with NGM Biopharmaceuticals, Inc as lead sponsor.

NCT NCT04068896
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04068896 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2 Dose-Finding Study Followed by Expansion Cohorts of NGM120, a GFRAL Antagonist Monoclonal Antibody Blocking GDF15 Signaling, in Subjects With Advanced Solid Tumors and Pancreatic Cancer Using Combination Therapy
Lead sponsor
NGM Biopharmaceuticals, Inc
Phase
Phase 1/2
Overall status
Completed
Start date
October 16, 2019
Completion date
January 8, 2024
Enrollment
89 (actual)
Sites
20

Conditions

As the registry lists them; a condition with its own page is linked.

bladder cancer, colorectal cancer, esophageal cancer, gastric cancer, head neck squamous cell carcinoma, melanoma, metastatic castration-resistant prostate cancer, non-small cell lung cancer, ovarian cancer, pancreatic cancer, prostate cancer